Results 181 to 190 of about 39,703 (285)

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Introduction Etripamil is a fast‐acting intranasally self‐administered calcium‐channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE‐303 is an
James E. Ip, Benoit Coutu, John H. Ip, Peter A. Noseworthy, Maria L. Parody, Farhad Rafii, Samuel F. Sears, Narendra Singh, Bruce S. Stambler, Naeem K. Tahirkheli, Juan Agudelo‐Uribe, Derek Hu, Silvia Shardonofsky, Muhammad B. Sheikh, Anita Holz, David B. Bharucha, A. John Camm   +16 more
wiley   +1 more source

Correlation of Antiarrhythmic Effects of Diphenylhydantoin with Digoxin-Induced Changes in Myocardial Contractility, Sodium-Potassium Adenosine Triphosphatase Activity, and Potassium Efflux

, 1973
Robert E. Goldstein, Stanley C. Penzotti, Karen Kuehl, KIRK H. PRINDLE, Clifford Hall, Elwood Titus, Stephen E. Epstein   +6 more
openalex   +1 more source

Cross reactivity of digitoxin and spironolactone in two radioimmunoassays for serum digoxin. [PDF]

, 1978
H Müller, H Bräuer, B Resch
openalex   +1 more source

The study of Digoxin efficacy in children with congenital Heart Disease with left to right shunt without heart failure in Buali hospital in Ardabil at 1389. [PDF]

According to the heavy Cost of digoxin syrup, it’s vast side effects and complications and it’s narrow therapeutic window and regarding that digoxin is prescribed with no clear indication, there was a need to perform a study in order to evaluate ...
امامزادگان, رامین, عباس زاده, حسین, میرزا رحیمی, مهرداد   +2 more
core   +1 more source

Patterns of Life‐Sustaining Treatment Preferences Among Seriously Ill Veterans

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Goals of care conversations and documentation of life‐sustaining treatment (LST) preferences through durable, portable medical orders are critical for aligning care with patient values. The stability of patient preferences over time remains uncertain, particularly among community‐dwelling adults.
Connie S. Cole, Paula R. Langner, Susan C. Miller, Ann Kutney‐Lee, Cari Levy, John Cashy, Mary Beth Foglia, Lucinda Potter, Kate H. Magid, Andrew Murray, Meaghann S. Weaver, Anna E. Barón, Mary Ersek   +12 more
wiley   +1 more source

The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man.

, 1977
F I Marcus, E Quinn, Herschella Horton, S Jacobs, Susan Pippin, Marvin Stafford, Charles F. Zukoski   +6 more
openalex   +1 more source

The Central Nervous System as a Site of Action for the Coronary Vasoconstrictor Effect of Digoxin [PDF]

, 1974
Hasan Garan, Thomas W. Smith, W J Powell
openalex   +1 more source

Digoxin toxicity due to interaction of digoxin with erythromycin. [PDF]

BMJ, 1989
M. R. Hall, S. K. Gilmour-White, D. L. Maxwell   +2 more
openaire   +3 more sources

Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was ...
Daniel S. Cheah, Kathryn Tsai, Krishna Prasad Kurpad, Yousra Khalid, Sanjay S. Mehta   +4 more
wiley   +1 more source

Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. [PDF]

, 1973
C Davidson, D G Gibson
openalex   +1 more source